A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer (NSCLC), but only among patients who are likely to have a poor outcome with the latter treatment type.
Specifically, patients predicted to have poor survival outcomes with epidermal growth factor receptor—tyrosine kinase inhibitors (EGFR–TKI) according to the proteomic test survived a median 3 months longer when treated with chemotherapy than their counterparts who received the EGFR–TKI erlotinib.
By contrast, neither treatment regimen was associated with superior overall survival among patients whose predicted outcomes were good.
Original report: http://bit.ly/1jugCqX
Source: medwire News